Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... the design and preclinical characterization of AP24534, ARIAD's investigational, multi-targeted kinase inhibitor. The paper, "AP24534, a Pan-BCR-ABL Inhibitor for Chronic ... AP24534 may offer important advantages by minimizing the development of mutation-based drugresistance." Treatment with BCR-ABL inhibitors is initially effective in ...
2009 NOV 16 ... pathogens including those commonly implicated in both cSSSI and CAP, as well as MRSA and multi-drug resistant Streptococcus pneumoniae (MDRSP). Posters ... of Forest Laboratories, Inc. "The continuing medical need to deal with emerging resistance to existing therapeutic options is clear and urgent. These results, along with our ...
2009 NOV 16 ... presented during The Liver Meeting. About Studies 102 and 103 Studies 102 and 103 were multi-center, randomized, double-blind Phase III clinical trials comparing Viread to ... Diseases and the European Association for the Study of the Liver. The U.S. Food and Drug Administration (FDA) approved Viread for chronic hepatitis B in adults in 2008 based on ... to resolution of chronic hepatitis B infection. Notably, no mutations associated with resistance to Viread developed in any patients up to 144 weeks of treatment. "The ...
2009 NOV 23 ... continuous exposure to cytotoxic drugs in order to investigate and try to overcome multi-drugresistance (MDR), a major factor in the failure of standard chemotherapy. ...
2009 NOV 23 ... evaluate, develop and acquire new promising antibiotic therapeutic treatments against multi-drug resistant infectious microorganisms in humans. Pyro is a development ... in Zoology from Valparaiso University. Dr. Moellering said: "antimicrobial resistance is a rapidly growing threat to human health and welfare. At a time when we desperately ...
2009 NOV 9 ... "Azole resistance in Candida albicans is frequently caused by the overexpression of multi-drug efflux pump genes MDR1, CDR1, and CDR2 due to gain-of-function mutations in the ...
2009 NOV 16 ... According to recent research from Beijing, People's Republic of China, "The HIV and multi-drug resistant tuberculosis (MDR-TB) epidemics are closely linked. In Thailand as part ... HIV/AIDS Co-Infection, AIDS, Acquired Immunodeficiency Syndrome, Drug Development, Drug Resistance, Epidemics, HIV, Human Immunodeficiency Virus Bacterial Infection, Mycobacteria, ...
2009 NOV 16 ... Patients: Predictors of Virological Response and DrugResistance Evolution in a Multi-Cohort Study. Infection, 2009;37(5):438-444). For more information, contact ...
2009 NOV 9 ... difficile associated diarrhea are also in the pipeline. Far fewer options to treat multi-drug resistant gram-negative infections exist, and new drug development is lagging ... and locally at the institutional level, as do patterns of antimicrobial susceptibility/resistance. These trends are often associated with local treatment practices (eg, use of ...
2009 NOV 16 ... were negative. Both recipients received a renal graft from the same donor and developed multi-drug resistant (MDR)-PA infections with bacterial phenotypes and resistances similar to ... Keywords: United States, Winston-Salem, Antibacterial, Antibiotic, Antimicrobial Resistance, Arteritis, Cardiology, Drug Development, Drug Resistance, Hemorrhage, Infectious ...
2009 NOV 23 ... the scope of microbial work on the evolution of group-beneficial traits to the case of multi-species communities, particularly those that affect human health. We examined whether ... Salmonella by ampicillin-resistant Escherichia coli in the presence of otherwise lethal drug concentrations. Proceedings of the Royal Society B - Biological Sciences, ... State:KY, Country:United States, Ampicillin, Antibacterial, Antibiotic, Antimicrobial Resistance, Drug Resistance, Drugs, Enzymes, Escherichia coli, Lactamase, Pharmaceuticals, ...
2009 NOV 9 ... no direct correlation with individual gene expression, there was strong correlation of multi-gene signatures for many of the single agents and combinations tested. For instance, ... tested. For instance, docetaxel activity showed some dependence on the expression of drug pumps, while cisplatin activity showed some dependence on DNA repair enzyme expression. ... molecular basis of the observed in vitro chemosensitivity of NSCLC lies within the known resistance mechanisms inherent to these patients' tumors," scientists in Portsmouth, the United ...
2009 NOV 23 ... medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the Company, in ... Diseases, Pharmaceutical, Professional Services, Fina, Technology, Antimicrobial Resistance, Cubist Pharmaceuticals, Drug Resistance, Pharmaceutical Business, Pharmaceutical ...
2009 NOV 23 ... officer of Tokai and managing general partner of Apple Tree Partners. "This proprietary multi-target mechanism marks a novel and promising approach to both treating CRPC and ... antigen (PSA) levels. Notably, TOK-001 is the first investigational new drug that decreases androgen receptor levels in prostate cancer cells and the only prostate ... or surgical castration can be effective initially in controlling prostate cancer, but resistance to these therapies usually occurs, rendering them ineffective after several years. CRPC ...
2009 NOV 16 ... and Shelley A. Hearne, managing director of the Pew Health Group in welcoming the multi-country initiative. "We are thrilled to see the United States and European ... and veterinary communities, prevention of both health care and community-associated drug-resistant infections, and strategies for improving the antimicrobial drug pipeline. The ... Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health ...
2009 NOV 9 ... by Western blotting and flow cytometry, that the levels of Bcr-Abl tyrosine kinase and multi-drugresistance p-glycoprotein were inconsistent among resistant clones. On the other ...
2009 NOV 23 ... unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities ... of blood pressure and has been a broadly pursued but extremely difficult target to drug within the pharmaceutical industry for many years. Within the bloodstream, renin ... in the renin-angiotensin system to induce vascular constriction and increase vascular resistance, correspondingly increasing blood pressure. Suppression of the renin angiotensin system ...
2009 NOV 23 ... lesion length was 12 cm, and average activation time was 126 seconds. About VPI VPI is a multi-disciplinary group of independent physicians who are nationally known experts in the ... Clinical Trials, Hospitals, Pharmaceutical, Radiology, Research, Science, Adverse Drug Effect, Adverse Drug Event, Adverse Drug Reaction, Anatomy, Angiology, ... Cardiovascular, Carotid Stent, Clinical Trial Research, Coronary Disease, Drug Resistance, FDA, Femoral Artery, Heart Attack, Heart Disease, Hypertension, Infarction, Kidney, ...
2009 NOV 23 ... is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I ... only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used alkylating ...
2009 NOV 23 ... is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I ... only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used alkylating ...
